December 05, 2023
1 min watch
Save
VIDEO: Rogaratinib shows efficacy in gastrointestinal stromal tumor
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Healio spoke with Sandra D’Angelo, MD, about a study of rogaratinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor presented at the Connective Tissue Oncology Society Annual Meeting.
“This is one of the first compounds that has shown to be efficacious in patients with [succinate dehydrogenase-deficient gastrointestinal stromal tumor]. Hopefully there will be more efforts with this particular pathway,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, said in the interview.
Reference:
- Merriam P, et al. Paper 84. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.